Exploring New Strategies for the Management of Nonalcoholic Steatohepatitis: NOT a Trivial Pursuit
Description
Supported by: Madrigal
Organized by: Medscape Education
Presenters:
Manal F. Abdelmalek, MD
Stephen A. Harrison, MD
Mary E. Rinella, MD
The incidence of nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), continues to rise globally along with an increase in obesity, type 2 diabetes, and other metabolic disorders. Patients at risk of MASH greatly benefit from early identification and intervention. Join us at this interactive, case-based symposium where you can see how your case management strategies compare with those of your peers. Don’t miss out!
Learning Objectives: Upon completion of this activity, participants will:
- Have increased knowledge regarding the prevalence and risk factors for NASH, and clinical data for new and emerging treatments for NASH
- Have greater competence related to evaluating risk of fibrotic disease and NASH in patients with risk factors
- Demonstrate greater confidence in their ability to Include new and emerging NASH treatments into treatment strategies
CME Hours: Maximum of 1.25 AMA PRA Category 1 Credit(s)™
For more information and to register, visit: https://www.medscape.org/symposium/nash-fall-2023